VxMRS
Voxel Systems is delivering the next generation of diagnostic technology to the medical, pharmaceutical, and research industries.
VxMRS™
Magnetic Resonance Imaging (MRI) machines scan tissues for water and fat molecules to generate a high-resolution image. Most existing MRI machines can also acquire biochemical data, which can now be processed with VxMRS™ to provide new insights to clinicians.
Biochemical Fingerprint
VxMRS™ is a proven breakthrough in magnetic resonance spectroscopy (MRS) that generates a wealth of new data from the biochemistry of human tissue and enables earlier disease detection.
Voxel is applying VxMRS™ processing for non-invasive, clinical diagnostic utility in Alzheimer’s, Dementias, Cancer, Traumatic Brain Injury, and other diseases
Technology
With over 20 years of development by an FDA research team, the patented VxMRS™ algorithm processes MRS scan data to yield significantly more metabolic information from human tissue.
These biochemical profiles are unique to various tissues, creating a biochemical fingerprint that is identifiable by VxMRS™, even in the earliest stages of disease.
In multiple FDA studies, VxMRS™ data processing increased the number of biochemical markers from 3 or 4 to nearly 100 for brain scans.
VxMRS™ data creates a new paradigm of diagnostics that leverage machine learning to replace visual interpretation of the generated biochemical spectrum.
As a fully functioning data processing software, Voxel has identified multiple applications in a wide range of markets and diseases and is engaging researchers and practitioners as clinical partners.
